GHRP-2 vs Ipamorelin
Growth Hormone Releasing Peptide · Growth Hormone Secretagogue
Here is how these two compounds compare, based on published research, not marketing claims.
GHRP-2
A broad-spectrum ghrelin agonist producing one of the largest GH pulses in the class; also raises cortisol and prolactin.
Ipamorelin
The most selective GH secretagogue documented; triggers GH release without raising cortisol, prolactin, or appetite.
GHRP-2
255 studies
61 human trials
Not FDA-Approved
Ipamorelin
48 studies
3 human trials
Not FDA-Approved
What it does
GHRP-2
Delivers a sharp acute growth hormone spike with the broader hormonal footprint of a first-generation ghrelin agonist. Cortisol and prolactin rise alongside the GH effect in trial data, the off-target activity that drove development of cleaner alternatives like ipamorelin. Best-studied compound of the GHRP class in early ghrelin-receptor research, and still appears in research contexts where robust acute GH response matters more than receptor selectivity.
Ipamorelin
Releases growth hormone without the cortisol or prolactin spike that older ghrelin agonists produced. The most receptor-selective compound in the GH secretagogue class for GHS-R1a, the ghrelin receptor itself. Comparable growth hormone elevation to GHRP-2 or GHRP-6 in head-to-head studies, without the hormonal collateral that made those compounds harder to study.
How it works
GHRP-2
GHRP-2 is a synthetic hexapeptide that activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs. Unlike the more selective ipamorelin, GHRP-2 produces robust GH release but also stimulates ACTH/cortisol secretion and prolactin elevation. The broader receptor activation profile produces a larger GH pulse but with more off-target hormonal effects. GHRP-2 also stimulates appetite through the same ghrelin pathway.
Ipamorelin
Ipamorelin acts on a single receptor on the pituitary gland (the ghrelin receptor, GHS-R1a) and triggers growth hormone release without touching the cortisol axis, the prolactin axis, or the appetite signal that older compounds in this class also activated. Other GH secretagogues like GHRP-6 and hexarelin raise cortisol alongside GH, raise prolactin, and sharpen hunger. Ipamorelin does not.
How often
GHRP-2
In published human pharmacokinetic and pharmacodynamic studies, GHRP-2 has been administered as subcutaneous or intravenous injection. No FDA-approved product exists. Research protocols vary in frequency and duration.
Ipamorelin
In published human pharmacokinetic studies (Johansen 1999), ipamorelin was given as a subcutaneous injection with dose-dependent GH response measured over hours. The Beck 2014 Phase II post-surgical trial used repeated dosing over days. Clinical protocols typically use daily subcutaneous injection, though this frequency derives from clinical practice rather than from controlled dose-optimization trials.
How strong
GHRP-2
Among the most potent GH secretagogues by peak GH elevation magnitude. Multiple published human studies documenting dose-dependent GH release. The compound has been used as a diagnostic tool in research settings to assess pituitary GH reserve.
Ipamorelin
Moderate GH elevation with the cleanest hormonal profile in the secretagogue class. The GH pulse follows the body's natural pulsatile pattern rather than producing sustained elevation. The selectivity advantage is the pharmacological identity of the molecule.
Main tradeoff
GHRP-2
Strong GH release but with cortisol and prolactin elevation that ipamorelin avoids. The broader hormonal profile makes GHRP-2 less selective than ipamorelin for pure GH research. Appetite stimulation can be pronounced. Not FDA-approved for any indication.
Ipamorelin
The selectivity that makes ipamorelin distinctive is well documented, but clinical outcome data beyond the single Phase II post-surgical GI trial (Beck 2014) is absent. One of the most widely used peptides in clinical practice has almost no published outcomes data for the endpoints practitioners actually prescribe it for. The CJC-1295 plus ipamorelin combination has never been tested in a controlled comparison study despite being the most common clinical protocol.
Best for
GHRP-2
- Research comparing selective (ipamorelin) versus non-selective (GHRP-2, GHRP-6) GH secretagogues
- Research on pituitary GH reserve assessment using pharmacological stimulation
- Research contexts where peak GH magnitude matters more than hormonal selectivity
Ipamorelin
- Research interest in selective GH secretagogues with minimal off-target hormonal effects
- Research comparing GH secretagogue selectivity profiles across the class
- Research contexts where the CJC-1295 plus ipamorelin pairing is the protocol under study
How to choose
A good fit for GHRP-2
- Research on pituitary GH reserve assessment using maximal pharmacological stimulation
- Research comparing selective versus non-selective GH secretagogues
- Research contexts where peak GH magnitude matters more than hormonal selectivity
A good fit for Ipamorelin
- Research on selective ghrelin-receptor GH release with zero off-target effects
- Clinical protocols where hormonal cleanliness is the primary consideration
- Research contexts where the CJC-1295 plus ipamorelin pairing is under study
Consider both across time
GHRP-2 and ipamorelin both activate the same ghrelin receptor but with very different downstream profiles. GHRP-2 produces a larger GH pulse but at the cost of cortisol elevation, prolactin elevation, and appetite stimulation. Ipamorelin produces a cleaner GH pulse without those off-target effects. Most researchers and clinicians have moved to ipamorelin for GH protocols because the selectivity advantage outweighs the modest GH magnitude difference. GHRP-2 retains value as a maximal-stimulation research tool and as a reference compound for understanding selectivity trade-offs in the class.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GHS-R1a Receptor
- GHS-R1a Receptor activates Pituitary Somatotrophs
- Pituitary Somatotrophs stimulates Growth Hormone Release; Anterior Pituitary connects to Growth Hormone Release
- GHS-R1a Receptor elevates Cortisol Elevation
- GHS-R1a Receptor elevates Prolactin Elevation
- GHS-R1a Receptor stimulates Appetite Stimulation
- GHS-R1a Receptor activates Ghrelin Mimicry
- Ghrelin Mimicry connects to Anterior Pituitary
- Growth Hormone Release connects to IGF-1 Elevation
GHRP-2 activates the ghrelin receptor with broad downstream signaling, producing robust GH release alongside cortisol and prolactin elevation.
Ipamorelin selectively binds the ghrelin receptor on pituitary somatotrophs to trigger growth hormone release without raising cortisol or prolactin.
Research Evidence
Both compounds have human pharmacodynamic data. GHRP-2 has been used as a diagnostic tool in research settings to assess pituitary GH reserve, with multiple published studies documenting dose-dependent GH release alongside cortisol and prolactin elevation. Ipamorelin has 48 published studies with human data confirming the selectivity profile (Raun 1998, Johansen 1999) and a Phase II post-surgical GI trial (Beck 2014). Neither has completed Phase III trials. The evidence bases are complementary: GHRP-2 is better characterized as a pharmacological challenge tool; ipamorelin is better characterized as a selective clinical peptide.
- 1.
If maximizing GH pulse magnitude is the only priority, GHRP-2 produces a stronger response.
- 2.
If minimizing cortisol and prolactin elevation matters, ipamorelin is clearly superior.
- 3.
If appetite stimulation is desired (e.g., for underweight patients), GHRP-2's appetite effect is useful.
- 4.
If appetite stimulation is a problem, ipamorelin avoids it.
Key Limitations
- •No direct head-to-head efficacy trial.
- •Both are non-FDA-approved research compounds.
- •GHRP-2's cortisol elevation may limit its suitability for chronic use.
- •Ipamorelin's selectivity mechanism is not fully elucidated.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
GHRP-2
"GHRP-2 is the best all-around growth hormone peptide"
Partially accurate
"GHRP-2 makes me extremely hungry"
Supported by evidence
Ipamorelin
"Ipamorelin is the cleanest GH secretagogue with the fewest side effects"
Plausible but unproven
"Combined with CJC-1295 it mimics natural GH pulsing"
Plausible but unproven
"It helped with my joint pain and recovery"
Anecdotal only
Safety Comparison
Ipamorelin has the cleaner safety profile: published pharmacodynamic data specifically documents the absence of cortisol, prolactin, and ACTH changes at GH-stimulating doses. GHRP-2 raises both cortisol and prolactin alongside GH, with appetite stimulation through ghrelin signaling. The cortisol and prolactin effects are documented across multiple studies and are inherent to GHRP-2's broader receptor activation profile, not idiosyncratic. Neither compound has long-term safety data.
GHRP-2
Elevates cortisol and prolactin alongside GH. Strong appetite stimulation. More off-target effects than newer secretagogues.
Ipamorelin
Minimal off-target effects. Does not significantly raise cortisol or prolactin. Side effects are generally mild.
What the Research Suggests
Ipamorelin is the better option for most people due to its selectivity. GHRP-2 has niche applications where maximal GH stimulation or appetite stimulation is specifically desired.